- Home
- AKR vs PTGX Comparison
AKR vs PTGX Comparison
Compare AKR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKR
- PTGX
- Stock Information
- Founded
- AKR 1993
- PTGX 2006
- Country
- AKR United States
- PTGX United States
- Employees
- AKR N/A
- PTGX N/A
- Industry
- AKR Real Estate Investment Trusts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- AKR Real Estate
- PTGX Health Care
- Exchange
- AKR Nasdaq
- PTGX Nasdaq
- Market Cap
- AKR 2.6B
- PTGX 2.8B
- IPO Year
- AKR 1993
- PTGX 2016
- Fundamental
- Price
- AKR $25.00
- PTGX $41.65
- Analyst Decision
- AKR Buy
- PTGX Strong Buy
- Analyst Count
- AKR 4
- PTGX 7
- Target Price
- AKR $22.00
- PTGX $53.57
- AVG Volume (30 Days)
- AKR 1.3M
- PTGX 700.6K
- Earning Date
- AKR 10-28-2024
- PTGX 11-07-2024
- Dividend Yield
- AKR 3.03%
- PTGX N/A
- EPS Growth
- AKR N/A
- PTGX N/A
- EPS
- AKR 0.10
- PTGX 2.68
- Revenue
- AKR $367,395,000.00
- PTGX $323,795,000.00
- Revenue This Year
- AKR N/A
- PTGX $396.93
- Revenue Next Year
- AKR $7.26
- PTGX N/A
- P/E Ratio
- AKR $239.55
- PTGX $15.15
- Revenue Growth
- AKR 7.51
- PTGX 125.73
- 52 Week Low
- AKR $14.72
- PTGX $16.80
- 52 Week High
- AKR $25.58
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- AKR 59.88
- PTGX 41.01
- Support Level
- AKR $24.30
- PTGX $33.31
- Resistance Level
- AKR $25.09
- PTGX $48.86
- Average True Range (ATR)
- AKR 0.45
- PTGX 2.82
- MACD
- AKR -0.04
- PTGX -0.62
- Stochastic Oscillator
- AKR 55.68
- PTGX 53.63
About AKR Acadia Realty Trust
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company's portfolios are located primarily in metropolitan areas of the United States. The company operates through three segments: core portfolio, which consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon and generates the majority of total revenue; funds, which comprises the funds launched by the trust; and structured financing, which consists of notes receivable and related interest income.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.